logo-loader
viewSkinBioTherapeutics PLC

SkinBioTherapeutics raise £4m to expand SkinBiotix technology in oral and healthcare

Skinbiotherapeutics Plc's (LON:SBTX) Doug Quinn talks to Proactive's Katie Pilbeam on their plans for the £4m raised from existing and new institutions to fund work on new product applications.

Quinn explains how they plan to expand skin biotics technology into oral and healthcare as well as establish a 'physical footprint of a lab'.

The funds will also be invested to expand the group’s research capabilities by adding its own facilities to those it uses at the University of Manchester.

Quick facts: SkinBioTherapeutics PLC

Price: 17 GBX

AIM:SBTX
Market: AIM
Market Cap: £21.83 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

SkinBioTherapeutics CEO hails 'significant scientific milestone' with...

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive's Andrew Scott soon after updating investors on the progress of its cosmetic skincare programme and plans for a psoriasis food supplement trial. Sederma, its partner in the cosmetics programme and a division of Croda...

on 3/8/20

2 min read